Introduction
According to findings in the Global Health Observatory data repository from 2011, malignant tumors caused more deaths than coronary heart diseases or stroke (
http://apps.who.int/gho/data/node.main.CODWORLD?lang=en). There were 14.1 million new cases and 8.2 million deaths from cancers in 2012 [
1]. Thus, studying the pathogenesis of malignant tumors is essential for identifying more therapeutic targets for cancer treatment.
Integrin alpha 2 (ITGA2) is the alpha subunit of a transmembrane receptor for collagens and related proteins [
2]. ITGA2 frequently forms a heterodimer α2β1 with a β subunit, which mediates the adhesion of platelets and other cells to the extracellular matrix (ECM) [
3,
4]. ITGA2 is overexpressed in several types of tumors, such as pancreatic cancer, gastric cancer, liver cancer, prostate cancer, and breast cancer [
5‐
9]. Recently, increasing evidence has suggested that ITGA2 might play an essential role in modulating tumor cell migration, invasion, and metastasis [
10,
11]. However, the specific mechanism of how ITGA2 is involved in all this is still confusing. Reportedly, the loss of ADAR1 could lead to the up-regulation of ITGA2 in hepatocellular carcinoma [
12]. Besides, the loss of ADAR1 overcomes resistance to immune checkpoint blockade in tumors [
13]. Therefore, we hypothesized that ITGA2 might also regulate immune checkpoint blockade responses in tumors.
The relationship between host and tumor is dynamic, and tumors can often escape from immune recognition and immune attack, which determines the clinical course of cancers. The aberrant activation of immune checkpoints is one of the characteristics of cancer cells escaping from host immune salience [
14,
15]. Importantly, the programmed cell death protein 1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway is one of the most studied immune checkpoint pathways to inactivate immune responses in the tumor microenvironment [
16]. Several studies have demonstrated that blocking PD-L1 can improve the immune functions of T cells in many malignant tumors [
17‐
20]. The PD-1/PD-L1 interaction could inhibit T cell response by inducing the apoptosis of CD8
+ T cells and promoting CD4
+ T differentiating to regulatory T cells [
21]. Moreover, PD-L1 expressed on the surface of malignant tumor cells could directly suppress the antitumor activity of CD8
+ T cells [
22]. Thus, the way to regulate PD-L1 expression levels in cancer cells is crucial to exploring novel therapeutic strategies to improve the immune checkpoint blockade effect on cancers.
In our current study, we showed that the expression level of ITGA2 was highly related to the ability of proliferation and invasion of tumor cells. We further revealed that ITGA2 interacted with STAT3 and up-regulated PD-L1 expression by increasing the phosphorylation of STAT3 in cancer cells. Collectively, these data suggest that ITGA2 could be a potential target for improving the anti-tumor efficiency of immune checkpoint-based therapies in cancer.
Materials and methods
Cell culture
The PANC-1, HepG2, SGC-7901, and MDA-MB-231 cell lines were purchased from ATCC. The Panc02 cell line was acquired from Tong Pai Technology (Shanghai, China). PANC-1, HepG2, and MDA-MB-231 cell lines were cultured in DMEM (Thermo Fisher Scientific, USA) supplemented with 10% FBS (HyClone, USA) at 37 °C in a 5% CO2 incubator. SGC-7901 cells were cultured in RPMI 1640 containing 10% FBS under similar conditions.
Antibodies and plasmids
Human expression vectors for flag-ITGA2 recombinant proteins were generated using the pcDNA3.1 backbone vector. The ITGA2 antibody (ab133557, 1:1000) was purchased from Abcam; GAPDH (10494–1-AP, 1:3000) from Proteintech; STAT3 (10253–2-AP, 1:1000) from Proteintech; PD-L1 (13684S, 1:1000) from Cell Signaling Technology; and Phospho-STAT3-Y705 (abs118973, 1:1000) from Absin.
RNA interference
The sh-Control and sh-ITGA2s were procured from Sigma-Aldrich. Lipofectamine 3000 (Invitrogen, USA) and Opti-MEM media (Invitrogen, USA) were used for the transfection reactions; lipofectamine 3000 was used to transfect 293 T cells to shRNA plasmids and viral packaging plasmids (pVSV-G and pEXQV). 24 h after transfection, the medium was replaced with fresh DMEM containing 10% FBS and 1 mM sodium pyruvate, and 48 h post-transfection, the virus culture medium was collected and added to the PANC-1, HepG2, SGC-7901, and MDA-MB-231 cells supplemented with 12 μg/ml of polybrene. 24 h after infection, the infected cells were selected with 10 μg/ml of puromycin. The shRNA sequence information is provided in the Additional file
1: Table S2.
Western blot analysis
Written informed consent was obtained from patients before surgery, as described previously [
23]. The use of human tissue was approved by the Ethics Committee of Tongji Medical College, HUST, China.
Cell lysates were prepared using a radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher Scientific, USA) in the presence of a protease inhibitor cocktail (Sigma-Aldrich, USA) and Halt phosphatase inhibitor cocktail (Thermo Scientific, USA). Protein concentration was determined using a protein quantification kit (Sigma-Aldrich, USA) to ensure equal amounts of total protein were loaded in each well of SDS-PAGE gels. The protein was transferred to PVDF membranes (Pierce Biotechnology, USA) eventually and blocked with 5% not-fat milk for 1 h at room temperature (RT), then incubated with the specific primary antibody at 4 °C overnight or at room temperature (RT) for 2 h and washed with PBS for 3 times, followed by another incubation with secondary antibodies (BOSTER, USA). Finally, after washing with PBS for 3 times, the membranes were exposed to X-ray films using ECL detection reagents (Thermo Fisher Scientific, USA).
Quantitative RT-PCR assay
Total RNA was prepared using a Trizol reagent (Invitrogen, 15,596,026, USA). RNA samples (1 μg) were reverse-transcribed using a PrimeScript™ RT reagent Kit (TAKARA, RR047A, JPN). Quantitative real-time PCR was performed using a TB Green™ Fast qPCR Mix kit (TAKARA, RR430A, JPN). The sequences of the primers used for qRT-PCR are shown in the Additional file
1: Table S1. Values represent the averages of three technical replicates from at least three independent experiments (biological replicates).
Immunohistochemistry (IHC)
Tissue microarray slides were purchased from Outdo Biobank (Shanghai, China) (HPan-Ade060CD-01). IHC analysis was performed with ITGA2 (Abcam, 1:5000), PD-L1 (CST, 1: 1000), and Phospho-STAT3-Y705 (Absin, 1:2000) antibodies to determine their protein expression levels. Two independent pathologists, who were uninformed about the patient data and histopathological features of the samples, were responsible for reviewing and scoring the degree of immunostaining separately. Staining intensity scoring was done, as described previously [
24].
The colony formation assay was performed to examine the biological effect of ITGA2 on tumor cell survival. 500 Tumor cells infected with sh-Control or sh-ITGA2s, pcDNA3.1, or flag-ITGA2 plasmids were plated in six-well plates, and colony formation assays were performed and photographed after 7–14 days of plating.
Cell invasion and migration assay
The transwell assay was employed to evaluate cell invasion using 24-well Corning Costar inserts with 8-μm pores precoated with Matrigel (BD, United States; diluted 1: 8) for 6 h in an incubator. To begin with, 1 × 104 cancer cells were planted into upper invasion chambers without FBS, and DMEM containing 30% FBS was introduced to the lower chambers. After a 12 to 24-h culture, cells were fixed on the insert membranes using methanol and stained with a Crystal Violet Staining Solution (Solarbio, China). The invading cells were photographed and evaluated under a microscope at five fields per well.
Transwell assay was employed again to examine cell migration using 24-well Corning Costar inserts with 8-μm pores without Matrigel-coating. Initially, 1 × 104 cancer cells were planted into upper chambers, and DMEM containing 30% FBS was placed in the lower chambers. After a 12 to 24-h culture, the cells were fixed on the insert membranes using methanol and stained with a Crystal Violet Staining Solution (Solarbio, China). The migrated cells were photographed and assessed under a microscope at five fields per well.
MTS assay
The proliferation ability of tumor cells was assessed using (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium) (MTS reagent) (Abcam, ab197010, USA). Briefly, 1000 cells were introduced into 96-well plates with 100 μl DMEM containing 10% FBS and treated with serial small molecular inhibitors under different concentration gradients. 20 μl of an MTS reagent was added to each well three hours before the end of the incubation period following the manufacturer’s instructions. The absorbance of each well was detected at 490 nm with a microplate reader.
Flow cytometry
PANC-1, HepG2, SGC-7901, and MDA-MB-231 cells infected with sh-Control or sh-ITGA2s were prepared and stained for flow cytometry with the following antibodies: isotype APC anti-human IgG Fc Antibody (Biolegend, clone HP6017, USA) or APC anti-human CD274 antibody (Biolegend, clone 29E.2A3, USA) or for 30 mins at 4 °C. The cells were then washed with PBS three times, resuspended in 150 μl staining buffer, and analyzed for flow cytometry.
For flow cytometry analysis of the mouse tissue samples, single-cell suspensions were prepared and stained for flow cytometry with the following antibodies: APC conjugated CD45 antibody (Biolegend, 103,112, USA); FITC conjugated CD4 antibody (Biolegend, 100,510, USA); PE-conjugated CD8 antibody (Biolegend, 100,708, USA); APC conjugated CD11b antibody (Biolegend,101,212, USA); and FITC conjugated Gr1 antibody (Biolegend, 108,406, USA). Flow cytometry was performed on BD FACSCelesta (BD Biosciences, USA), and the data were analyzed using FlowJo.
GEPIA (
http://gepia.cancer-pku.cn/) and Human Protein Atlas cancer databases (
https://www.proteinatlas.org/) were mined to predict the ITGA2 differential expression level in cancerous and healthy groups. The survival analyses, performed by GEPIA for hypothesis evaluation, used a log-rank test based on gene expression levels. Gene correlation analyses conducted by Pearson correlation statistics were carried out with GEPIA for all the given sets of GTEx and TCGA expression data.
Generation of PDAC xenografts in nude mice
Athymic nude (nu/nu) mice (4–5 weeks old, male) were purchased from Vitalriver (Beijing, China). 5 × 106 PANC-1 human pancreatic cancer cells infected with sh-Control or sh-ITGA2 lentivirus were dispersed in a 100 μl solution of PBS and then inoculated subcutaneously into the left dorsal of the nude mice. Tumor sizes were measured with a digital Vernier caliper every two days for a total of 21 days. Tumor volumes were calculated using the formula: tumor volume (mm3) = (L x W2)/2. The animals were sacrificed on day 21 or when tumor volume reached 1000 mm3. The experimental procedures with nude mice were conducted per the guidelines approved by our local ethics committee (Tongji Medical College, HUST, China).
Syngeneic tumor model treatment protocol
All experimental procedures with nude mice were conducted per the guidelines approved by the local ethics committee (Tongji Medical College, HUST, China). C57BL/6 mice (6–8 weeks male, Vitalriver, Beijing, China) were subcutaneously injected at the right flank with 5 × 106 Panc02 cells infected with sh-Control or sh-ITGA2 #1 lentivirus and diluted in 100 μl solution (PBS and Matrixgel, 1:1 ratio). Tumor lengths and widths were measured every day with a digital caliper, and tumor volumes were calculated using the formula: (L x W2)/2. When the tumor size reached approximately 50 mm3, mice with analogous types of tumors were divided randomly into two groups and injected intraperitoneally with 200 μg of anti-PD-1 antibody (BioXcell, Clone RMP1–14, USA) or 200 μg of IgG (BioXcell, Clone 2A3, USA) (given at days 0, 3, 6). Mice were euthanized once the tumor volumes reached 200 mm3, and their tumors were harvested.
Immunoprecipitation
A 0.5–2.0 μg primary antibody was added to the cell lysate sample and incubated on ice overnight. The next day, 20–50 μL of Protein A beads (CST, #9863, USA) was added to the cell lysate and primary antibody mixture, and the content was gently rotating incubated at 4 °C for 3 h. The next day, the beads were washed at least six times with lysate buffer on ice, and then subjected to western blotting analysis.
Statistical analysis
GraphPad Prism 6 software (GradPad Software, Inc) was used for all statistical analyses. Statistical significance was assessed using the paired t-test, Student’s t-test, and one or two-way ANOVA, followed by Tukey’s multiple comparison tests. Only P values less than 0.05 were considered significant. All the values are expressed as the mean ± SD.
Discussion
Integrins are essential in mediating cell-matrix and cell-cell interactions as heterodimeric proteins on the cell surface that have been confirmed to participate in the processes of tumor initiation, progression, and metastasis [
27,
28]. As a subunit of integrin, ITGA2 is closely associated with tumor cell proliferation, migration, and invasion [
29]. The high expression of ITGA2 contributes to the reduced survival rate of solid cancer. Consistent with this fact, our results revealed that ITGA2 was abnormally over-expressed in many malignant tumors, including pancreatic cancer, gastric cancer, liver cancer, and breast cancer. Furthermore, our data demonstrated that knocking down ITGA2 inhibited cancer cell proliferation (Fig.
2 and Fig.
4), but the overexpression of ITGA2 promoted tumor cell proliferation (Fig.
3 and Fig.
4). Interestingly, our data also established that the expression of ITGA2 was most up-regulated in PDAC, suggesting that ITGA2 might play an essential role in the pathogenesis of PDAC. Additionally, our findings point to ITGA2 acting as an oncogenic protein to promote the progression of solid cancer, especially pancreatic cancer.
Cancer is a complex disease process that involves the interaction between the tumor and the host immune system [
30]. Several studies have reported that the number of immune infiltration cells increases in cancer, but most of the augmented immune cells are immunosuppression-related cells, such as regulatory T-cell (Treg), M2 macrophages (M2), and myeloid-derived suppressor cells (MDSC) [
31‐
33]. Additionally, increased immunosuppression-related cells correlate with poor survival in various types of malignant tumors, but Treg and MDSC depletion therapy can delay tumor growth in vivo [
33,
34]. Per these reports, the dynamic network among immune cells themselves suggests a key role of the network in tumor progression and behaviors. Understanding the mechanism of how to down-regulate the infiltration of tumor suppression immune cells and up-regulate tumor-killing immune cells is essential to improving the efficiency of immune therapy. In this study, we found that ITGA2 inhibition increased the ratio of tumor-killing lymphocytes and decreased the proportion of immunosuppression-related cells in tumors (Fig.
7), which suggests that ITGA2 might be an ideal candidate for immune therapy.
The PD-1/PD-L1 immune checkpoint blockade allows to potentiate antitumor immunity by inhibiting immunosuppressive signals from co-inhibitory molecules, and this has achieved great success in many malignant tumors [
35‐
39]. The interaction between PD-L1 on tumor cells and PD-1 on T-cells inhibits the biological functioning of antigen-specific CD8
+T cells and conduces cancer cells to escape immune destruction [
40,
41]. Therefore, how to inhibit the PD-L1 expression of cancer cells is essential to cancer immune therapy. Encouragingly, Guo P et al. reported that targeting ITGA2 improved the antitumor efficacy of immune therapy in glioblastoma multiforme (GBM) [
42]. Here, our RNA-seq analysis showed that PD-L1 expression and the PD-1 checkpoint pathway were selectively downregulated after knocking down ITGA2 in PANC-1 cells. Meanwhile, we also found that ITGA2 transcriptionally increased PD-L1 expression in multiple types of cancer cells. Moreover, ITGA2 repression enhanced the tumor inhibition effect of the anti-PD-1 antibody in vivo. These results suggest that ITGA2 might be critical in modulating the anti-tumor efficiency of immune checkpoint-based therapy.
It has been reported that miR-16-5p inhibits tumor progression by down-regulating ITGA2 in colorectal cancer [
43]. ADAR1 also reportedly enhances hepatocellular carcinoma (HCC) metastasis by promoting tumor cell adhesion to ECM via increasing ITGA2 expression [
8,
42]. Furthermore, blocking ITGA2 inhibits gastric cancer and glioblastoma (GBM) cell migration of [
42]. However, the specific biological mechanism of how the expression of ITGA2 correlates with the progression of cancer and the blockade of ITGA2 inhibits the migration of cancer cells has remained unknown for a long time. Here, we demonstrated that ITGA2 might regulate cancer cell proliferation and migration by regulating the expression of PD-L1.
Recently, several studies have shown that various transcriptional factors, such as STAT1 [
44], STAT3 [
45], BRD4 [
23], NF-kB [
18], PI3K/AKT/mTOR [
46], and MEK1/2/ERK1/2 [
47], promoted PD-L1 transcription in cancer cells. By carrying out a drug sensitivity assay and several verification experiments, we determined that ITGA2 bound with STAT3 to initiate the transcription of PD-L1 by increasing the phosphorylation level of STAT3 in cancer cells. Therefore, ITGA2 is potentially a new regulator of PD-L1 expression, and this regulation might be attributed to the activation of the STAT3 signaling pathway. All our findings suggest that more research has to be carried out on the use of ITGA2 as a novel immune therapeutic target for malignant tumors.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.